This summary was created by AI, based on 2 opinions in the last 12 months.
Agios Pharmaceuticals Inc. (AGIO-Q) has been highlighted as a promising investment opportunity by multiple experts, specifically for its advancements in cancer treatment drugs. The company is on track to commercialize two additional products within the next year, which are expected to significantly enhance cash flows. With a current trading valuation of 3x earnings and 1.2x book value, AGIO demonstrates a strong financial profile supported by a notable Return on Equity (ROE) of around 57%. The experts suggest setting stop-loss levels at $21 to protect investments, while aiming for price targets ranging from $41 to $57, indicating an upside potential of approximately 28%. Despite its high growth prospects, AGIO does not currently offer a dividend yield to its investors.
Agios Pharmaceuticals Inc. is a American stock, trading under the symbol AGIO-Q on the NASDAQ (AGIO). It is usually referred to as NASDAQ:AGIO or AGIO-Q
In the last year, there was no coverage of Agios Pharmaceuticals Inc. published on Stockchase.
Agios Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Agios Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Agios Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2025-03-19, Agios Pharmaceuticals Inc. (AGIO-Q) stock closed at a price of $31.47.
We reiterate AGIO as a TOP PICK. The developer of cancer treatment drugs expects two more products to go commercial over the next year- each with the potential to grow cash flows substantially. It trades at 3x earnings, 1.2x book and supports and supports a robust 57% ROE. We recommend trailing up the stop (from $21) to $25, looking to achieve $41 — upside potential of 28%. Yield 0%
(Analysts’ price target is $54.57)